Abstract
The global diabetes market is expected to have several key product launches in
the next few years; non-invasive insulins have high forecast sales, including
Pfizer?s inhaled insulin Exubera, due to be launched this year. New emerging
classes of OADs (oral antidiabetics) are also anticipated to drive sales, such
as DPP-IV inhibitors and GLP-1 agonists, enabling pharmaceutical companies to
diversify revenue streams and gain first to market advantage in these emerging
drug classes. ?The Diabetes Market Outlook to 2011? is a new management report
which provides in-depth insights into new product launches, upcoming patent
expiries and on-going clinical trials in order to predict changes in global
market dynamics. Key R&D trends are analyzed and pipeline compounds of the top
players are evaluated, enabling you to strengthen your position in the
diabetes market and anticipate future product success. Use this new report to
assess future high-potential diabetic therapies and understand the direction
of the diabetes market over the next 5 years.
View Cart
